AS Latvijas Juras medicinas centrs Valuation

Q: What is the Fair Price of UOM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

UOM (€6.7) is trading above our estimate of [[fair value]] (€2.24)

Is UOM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of UOM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: UOM (€6.7) is trading above our estimate of fair value (€2.24)

Significantly Below Fair Value: UOM is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UOM?

Key metric: As UOM is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for UOM. This is calculated by dividing UOM's market cap by their current revenue.
What is UOM's PS Ratio?
PS Ratio	0.5x
Sales	€10.23m
Market Cap	€5.36m

UOM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.5x
Enterprise Value/EBITDA	6.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does UOM's PS Ratio compare to its peers?

The above table shows the PS ratio for UOM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.2x
EIF MedNation	0.1x	n/a	€4.9m
JTH Gesundheitswelt Chiemgau	0.3x	n/a	€23.8m
MAK Maternus-Kliniken	0.3x	n/a	€33.1m
MED MEDICLIN	0.2x	0.7%	€123.5m
UOM AS Latvijas Juras medicinas centrs	0.5x	n/a	€5.4m

Price-To-Sales vs Peers: UOM is expensive based on its Price-To-Sales Ratio (0.5x) compared to the peer average (0.2x).

Price to Sales Ratio vs Industry

How does UOM's PS Ratio compare vs other companies in the DE Healthcare Industry?

2 Companies	Price / Sales	Estimated Growth	Market Cap
EIF MedNation	0.1x	n/a	US$5.15m
TLIK Arzneiwerk VIDA	0.08x	n/a	US$4.89m

No more companies available in this PS range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: UOM is good value based on its Price-To-Sales Ratio (0.5x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is UOM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UOM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate UOM's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Ship Healthcare Holdings

JP¥198.5b

Engages in the medical, healthcare, welfare, and nursing care businesses worldwide.

5EZ

JP¥12.50

-0.8%

-3.1%

Shandong Weigao Group Medical Polymer

HK$20.7b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

-6.2%

-37.3%

LNA Santé

€241.3m

Engages in the management and operation of health establishments.

2N3

€22.65

-9.4%

10.2%